Denali Therapeutics Inc.
NASDAQ:DNLIBiotechnology
+$0.09 today
- Market cap
- $2.95B
- Beta
- 1.01
- P/E (TTM)
- -8.7
- EPS (TTM)
- -$2.72
Volume 2.37M
Average 1.84M
DNLI Common Stock
The par or stated value of issued common shares, plus paid-in capital where reported together.
Denali Therapeutics Inc.NASDAQ: DNLI
Common Stock · Q2 FY2026 · quarter ended Jun 2026
Common stock rises 7.9% from a year ago
Common stock stood at $1.92M at the end of Q2 FY2026, up 7.9% from a year earlier and up 0.6% from the prior quarter. Over 3 fiscal years it compounded at +3.8% a year.
Context
- Common stock amounted to 0.2% of total assets at the end of Q2 FY2026, unchanged from a year earlier.
- Common stock increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether common stock keeps rising in the next quarterly balance sheet after a +7.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Common Stock history
USD · from the balance sheet
- Latest · FY2025
- 1.89M USD
- Year-over-year change
- +6.8%
- 4-year CAGR
- +5.1%
| Period | Period end | Common Stock | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.89M | +6.8% |
| FY2024 | 2024-12-31 | 1.77M | +3.3% |
| FY2023 | 2023-12-31 | 1.71M | +1.5% |
| FY2022 | 2022-12-31 | 1.69M | +8.9% |
| FY2021 | 2021-12-31 | 1.55M | — |
Common Stock vs competitors
How DNLI compares with its peers on the latest reported figures
- DNLI's Jun 2026 common stock of $1.92M is the 2nd highest of the 11 companies compared; the peer median is $33K.
- Its year-over-year change of +7.9% is the 7th highest of 10, against a peer median of +18.2%.
- Common stock amounts to 0.2% of total assets for DNLI, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $2.14B | +22.7% | +46.5% | 576.9% | |
| Jun 2026 | $1.92M | +7.9% | +3.8% | 0.2% | |
| Sep 2026 | $166K | +3.1% | +4.7% | 0.0% | |
| Sep 2026 | $100K | +0.0% | +0.0% | 0.0% | |
| Mar 2026 | $90K | +45.2% | +45.9% | 0.2% | |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $48K | +29.7% | +15.7% | 0.0% |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $18K | +12.5% | +78.3% | 0.0% |
| Sep 2026 | $15K | +7.1% | +44.2% | 0.0% | |
| Sep 2026 | $13K | +18.2% | +16.3% | 0.0% | |
| Mar 2026 | $11K | +22.2% | +11.2% | 0.0% | |
| Jun 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding DNLI) | $33K | +18.2% | +16.3% | 0.0% | |
Competitors are the stored peer set for DNLI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 293.48M | 218.04M | 127.11M | 174.96M | 205.33M |
| Short-term Investments | 571.93M | 1.12B | 907.41M | 657.37M | 662.55M |
| Net Receivables | 1.23M | 9.28M | 3.42M | 2.17M | 2.18M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 0 | 0 | 0 | 30.6M |
| Total Current Assets | 897.23M | 1.37B | 1.06B | 864.44M | 900.66M |
| Property, Plant & Equipment (Net) | 69.61M | 74.52M | 71.64M | 125.63M | 119.94M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 425.45M | 1.5M | 0 | 359.37M | 98.32M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 11.87M | 11.9M | 18.14M | 24.74M | 25.94M |
| Total Non-current Assets | 506.93M | 87.92M | 89.78M | 509.74M | 244.2M |
| Total Assets | 1.4B | 1.46B | 1.15B | 1.37B | 1.14B |
| Account Payables | 4.78M | 2.79M | 9.48M | 11.14M | 3.33M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 320.3M | 290.05M | 0 | 0 | 0 |
| Other Current Liabilities | 19.01M | 17.09M | 21.59M | 38.86M | 53.28M |
| Total Current Liabilities | 378.25M | 363.92M | 77.98M | 102.21M | 98.35M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 4.69M | 479K | 0 | 0 | 0 |
| Other Non-current Liabilities | 379K | 379K | 0 | 5.62M | 5.53M |
| Total Non-current Liabilities | 63.63M | 53.89M | 44.98M | 42.29M | 32.74M |
| Total Liabilities | 441.87M | 417.81M | 122.96M | 144.5M | 131.09M |
| Common Stock | 1.55M | 1.69M | 1.71M | 1.77M | 1.89M |
| Retained Earnings | (645M) | (970.99M) | (1.12B) | (1.54B) | (2.05B) |
| Accumulated OCI | (2.5M) | (6.89M) | 643K | 2.02M | 682K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 962.29M | 1.04B | 1.03B | 1.23B | 1.01B |
| Total Debt | 64.01M | 60.35M | 52.24M | 48.71M | 36.76M |
| Net Debt | (229.47M) | (157.69M) | (74.87M) | (126.25M) | (168.57M) |
Denali Therapeutics Inc.
NASDAQ:DNLI
Intrinsic Alpha fair value
Locked
Current Price
$18.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.